At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Brilacidin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation
In Brief
A Phase 2 clinical trial evaluating Brilacidin and Placebo for Head and Neck Neoplasms and Mucositis. Completed, enrolled 61 participants across 16 sites.
Detailed Summary
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral mucositis in patients undergoing chemoradiation for treatment of head and neck cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Neoplasms, Mucositis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
First PostedDec 2014
Primary CompletionOct 2017
Study CompletionNov 2017
TodayJul 2026
First PostedDec 24, 2014
Enrollment StartAug 14, 2014
Primary CompletionOct 25, 2017
Study CompletionNov 22, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.5 years ago
Interventions
Brilacidindrug
Oral Rinse used 3 times daily for 7 weeks
Placeboother